EXEL News & Events

Exelixis announced results from a subgroup analysis of the phase 3 Cabinet trial, which showed that Cabometyx provided significant improvements in progression-free survival versus placebo in patients with previously treated advanced neuroendocrine tumors, NET, regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting to be held from May 29 - June 2 in Chicago. These subgroup results presented today at ASCO 2026 show cabozantinib demonstrated improvements in PFS regardless of functional status. In patients with non-functional NET, the hazard ratio was 0.26; median PFS was 9.4 months with cabozantinib versus 3.1 months with placebo. In patients with functional NET, the HR was 0.40; median PFS was 12.7 months with cabozantinib versus 5.4 months with placebo.

Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and Canada, to supply Keytrude Qlex injection for subcutaneous administration in combination with zanzalintinib in Stellar-316, a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer, CRC. Under the terms of the clinical development collaboration with Merck, Exelixis is sponsoring the Stellar-316 pivotal trial, and Merck will supply Keytrude Qlex.